These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 37748491)
1. CAR T-cell therapy in autoimmune diseases. Schett G; Mackensen A; Mougiakakos D Lancet; 2023 Nov; 402(10416):2034-2044. PubMed ID: 37748491 [TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases. Lyu X; Gupta L; Tholouli E; Chinoy H Rheumatology (Oxford); 2024 May; 63(5):1206-1216. PubMed ID: 37982747 [TBL] [Abstract][Full Text] [Related]
3. Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? Shah K; Leandro M; Cragg M; Kollert F; Schuler F; Klein C; Reddy V Clin Exp Immunol; 2024 Jun; 217(1):15-30. PubMed ID: 38642912 [TBL] [Abstract][Full Text] [Related]
4. Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as the Future of Systemic Lupus Erythematosus Treatment. Kambayana G; Surya Rini S Curr Rheumatol Rev; 2023 Jun; 19(3):260-269. PubMed ID: 36786138 [TBL] [Abstract][Full Text] [Related]
5. Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production. Dingfelder J; Aigner M; Taubmann J; Minopoulou I; Park S; Kaplan CD; Cheng JK; Van Blarcom T; Schett G; Mackensen A; Lutzny-Geier G Transplant Cell Ther; 2024 Jun; 30(6):582.e1-582.e10. PubMed ID: 38548226 [TBL] [Abstract][Full Text] [Related]
6. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Schett G; Müller F; Taubmann J; Mackensen A; Wang W; Furie RA; Gold R; Haghikia A; Merkel PA; Caricchio R; D'Agostino MA; Locatelli F; June CH; Mougiakakos D Nat Rev Rheumatol; 2024 Sep; 20(9):531-544. PubMed ID: 39107407 [TBL] [Abstract][Full Text] [Related]
7. CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome. Pecher AC; Hensen L; Klein R; Schairer R; Lutz K; Atar D; Seitz C; Stanger A; Schneider J; Braun C; Schmidt M; Horger M; Bornemann A; Faul C; Bethge W; Henes J; Lengerke C JAMA; 2023 Jun; 329(24):2154-2162. PubMed ID: 37367976 [TBL] [Abstract][Full Text] [Related]
8. In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells. Zhang B; Wang Y; Yuan Y; Sun J; Liu L; Huang D; Hu J; Wang M; Li S; Song W; Chen H; Zhou D; Zhang X Ann Rheum Dis; 2021 Feb; 80(2):176-184. PubMed ID: 32998865 [TBL] [Abstract][Full Text] [Related]
9. CAR T cells for treating autoimmune diseases. Blache U; Tretbar S; Koehl U; Mougiakakos D; Fricke S RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996128 [TBL] [Abstract][Full Text] [Related]
10. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Mackensen A; Müller F; Mougiakakos D; Böltz S; Wilhelm A; Aigner M; Völkl S; Simon D; Kleyer A; Munoz L; Kretschmann S; Kharboutli S; Gary R; Reimann H; Rösler W; Uderhardt S; Bang H; Herrmann M; Ekici AB; Buettner C; Habenicht KM; Winkler TH; Krönke G; Schett G Nat Med; 2022 Oct; 28(10):2124-2132. PubMed ID: 36109639 [TBL] [Abstract][Full Text] [Related]
11. CAR T-Cell Therapy in Autoimmune Disease. Howard JF; Vu T; Mozaffar T N Engl J Med; 2024 May; 390(17):1629-1631. PubMed ID: 38692299 [No Abstract] [Full Text] [Related]
12. CAR T-Cell Therapy in Autoimmune Disease. Merkt W; Lorenz HM; Schmitt M N Engl J Med; 2024 May; 390(17):1628-1629. PubMed ID: 38692297 [No Abstract] [Full Text] [Related]
13. CAR T-Cell Therapy in Autoimmune Disease. De Benedetti F; Diomedi Camassei F; Locatelli F N Engl J Med; 2024 May; 390(17):1629. PubMed ID: 38692298 [No Abstract] [Full Text] [Related]
14. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Kansal R; Richardson N; Neeli I; Khawaja S; Chamberlain D; Ghani M; Ghani QU; Balazs L; Beranova-Giorgianni S; Giorgianni F; Kochenderfer JN; Marion T; Albritton LM; Radic M Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842314 [TBL] [Abstract][Full Text] [Related]
15. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Wang W; He S; Zhang W; Zhang H; DeStefano VM; Wada M; Pinz K; Deener G; Shah D; Hagag N; Wang M; Hong M; Zeng R; Lan T; Ma Y; Li F; Liang Y; Guo Z; Zou C; Wang M; Ding L; Ma Y; Yuan Y Ann Rheum Dis; 2024 Sep; 83(10):1304-1314. PubMed ID: 38777376 [TBL] [Abstract][Full Text] [Related]
16. Is There a Place for Chimeric Antigen Receptor-T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases? Orvain C; Boulch M; Bousso P; Allanore Y; Avouac J Arthritis Rheumatol; 2021 Nov; 73(11):1954-1965. PubMed ID: 34042325 [TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes. Schultz L Front Immunol; 2020; 11():1985. PubMed ID: 32849662 [TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment? Sadeqi Nezhad M; Seifalian A; Bagheri N; Yaghoubi S; Karimi MH; Adbollahpour-Alitappeh M Front Immunol; 2020; 11():603237. PubMed ID: 33324420 [TBL] [Abstract][Full Text] [Related]
20. Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus. Radic M; Neeli I; Marion T Expert Opin Biol Ther; 2022 Apr; 22(4):499-507. PubMed ID: 35089116 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]